Skip to main content
Log In
More
Log in via Institution
Log in via OpenAthens
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
Basket
Search
More
Search for this keyword
Advanced search
Latest content
Archive
Authors
About
Podcasts
Search for this keyword
Advanced search
Close
More
Main menu
Latest content
Archive
Authors
About
Podcasts
Log in
More
Log in via Institution
Log in via OpenAthens
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
BMJ Journals
You are here
Home
Archive
Volume 11, Issue Suppl 2
621 Risk of damage progression with belimumab versus oral immunosuppressant use in patients with systemic lupus erythematosus
Email alerts
Article metrics
Article menu
Article
Text
Article
info
Citation
Tools
Share
Rapid Responses
Article
metrics
Alerts
PDF
Epidemiology & Outcomes
621 Risk of damage progression with belimumab versus oral immunosuppressant use in patients with systemic lupus erythematosus
Online download statistics by month:
Online download statistics by month: May 2024 to October 2024
Abstract
Full
Pdf
May 2024
55
0
20
Jun 2024
93
0
17
Jul 2024
66
0
10
Aug 2024
43
0
3
Sep 2024
57
0
6
Oct 2024
34
0
3
Total
348
0
59
Read the full text or download the PDF:
Subscribe
Log in
Log in via Institution
Log in via OpenAthens
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?